Skip to Content
Merck
  • Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens Connections.

Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens Connections.

eNeuro (2017-03-10)
Chongbo Zhong, Wendy Akmentin, Chuang Du, Lorna W Role, David A Talmage
ABSTRACT

Altered neuregulin 1 (Nrg1)/ErbB signaling and glutamatergic hypofunction have been implicated in the pathophysiology of schizophrenia. Here, we employed gene chimeric ventral hippocampus (vHipp)-nucleus accumbens (nAcc) coculture from mouse, electrophysiology, immunocytochemistry, FM1-43 vesicle fusion, and electron microscopy techniques to examine the pre- and postsynaptic mechanisms of genetic deficits in Nrg1/ErbB signaling-induced glutamatergic dysfunctions. Reduced presynaptic type III Nrg1 expression along vHipp axons decreases the number of glutamate synapses and impairs GluA2 trafficking in the postsynaptic nAcc neurons, resulting in decreased frequency and amplitude of miniature EPSCs (mEPSCs). Reduced expression of axonal type III Nrg1 along vHipp projections also decreases functional synaptic vesicle (SV) clustering and vesicular trafficking to presynaptic vHipp axonal terminals. These findings suggest that Nrg1/ErbB signaling modulate glutamatergic transmission via both pre- and postsynaptic mechanisms.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Glutamate Receptor 2 Antibody, extracellular, clone 6C4, clone 6C4, Chemicon®, from mouse
Sigma-Aldrich
Monoclonal Anti-PSD95 antibody produced in mouse, clone 7E3-1B8, purified immunoglobulin, buffered aqueous solution